Switching from Candesartan to Sacubitril/Valsartan in HFrEF
Stop candesartan and start sacubitril/valsartan 24/26 mg twice daily the same day or next day without any washout period, then double the dose every 2-4 weeks to the target of 97/103 mg twice daily. 1
No Washout Required for ARB-to-ARNI Transition
- Unlike ACE inhibitors which require a mandatory 36-hour washout, ARBs like candesartan can be stopped and sacubitril/valsartan started immediately because the risk of angioedema is not elevated when combining neprilysin inhibition with ARB therapy. 1, 2
- The ACC explicitly states patients can stop their ARB and start sacubitril/valsartan the same day or next day. 1
Starting Dose Selection
For your patient on candesartan ≤8 mg daily, start sacubitril/valsartan at 24/26 mg twice daily. 1, 3
The dosing logic is straightforward:
- Low-dose ARB (candesartan ≤8 mg or valsartan <160 mg daily): Start 24/26 mg twice daily 1, 3
- High-dose ARB (valsartan ≥160 mg daily): Start 49/51 mg twice daily 1
Your patient meets criteria for the lower starting dose since candesartan ≤8 mg is considered low-to-medium dose ARB therapy. 1
Titration Protocol
Double the dose every 2-4 weeks as tolerated:
- Week 0: 24/26 mg twice daily
- Week 2-4: 49/51 mg twice daily
- Week 4-8: 97/103 mg twice daily (target maintenance dose) 1, 3
The ACC guidelines support this aggressive titration schedule, with monitoring at each step before advancing. 2
Monitoring Requirements
Check blood pressure, serum creatinine, and potassium within 1-2 weeks after each dose initiation or increase. 1, 2
Your patient's baseline parameters are favorable:
- SBP ≥100 mm Hg: Adequate (though note that sacubitril/valsartan has more significant BP-lowering effect than ARBs alone) 4
- eGFR ≥30 mL/min/1.73 m²: No dose adjustment needed 5
- Potassium ≤5.0 mmol/L: Safe to initiate 5
Critical Safety Considerations
Do not permanently discontinue or reduce dose for:
- Asymptomatic hypotension (unless symptomatic or SBP consistently <90 mm Hg) 4
- Mild transient creatinine elevation 4
- Mild hyperkalemia 4
Absolute contraindications to verify absence of:
- History of angioedema with ACE inhibitor or ARB 5
- Pregnancy 5, 3
- Severe hepatic impairment (Child-Pugh C) 5
- Concomitant ACE inhibitor use within 36 hours 5, 3
Special Consideration for Borderline Blood Pressure
Research from the TITRATION study showed that even patients with SBP 100-110 mm Hg achieved the target dose in 72.7% of cases, with better success using gradual (6-week) versus rapid (3-week) titration (80% vs 69%). 6 If your patient's SBP is at the lower end (100-110 mm Hg), consider the slower end of the titration window (every 4 weeks rather than every 2 weeks) to maximize tolerability. 6
Clinical Benefit Justification
The 2022 AHA/ACC/HFSA guidelines provide a Class 1, Level B-R recommendation for replacing ARBs with sacubitril/valsartan in chronic symptomatic HFrEF NYHA class II-III patients to reduce morbidity and mortality. 1 PARADIGM-HF demonstrated a 20% relative reduction in cardiovascular death or heart failure hospitalization compared to enalapril. 1, 7
Common Pitfall to Avoid
Do not delay the switch waiting for "optimal" conditions or unnecessarily prolonged observation periods. The evidence supports direct switching in appropriately selected patients, and delaying therapy means delaying mortality benefit. 5 Your patient meets all criteria for immediate transition.